Group 1 - The core viewpoint of the article highlights the recent fluctuations in the ChiNext Index, which rose by 1.8% initially but then fell by 1.7% in the afternoon, indicating a period of adjustment following a strong start to the week [1] - The strong performance of the ChiNext Index in January is attributed to a combination of policy and industrial catalysts, particularly the implementation of the "AI + Manufacturing" policy and the global resonance of the AI industry, which has positively impacted sectors like commercial aerospace and brain-computer interfaces [1] - The sentiment improvement expected by early 2026 is anticipated to lead to upward corrections, with moderate growth in trading volume and restrained leverage and trading behaviors, suggesting that the market has not yet reached an irrational surge phase [1] Group 2 - The ChiNext focuses on new productive forces, aligning well with the national strategy of becoming a technology powerhouse [1] - The E Fund ChiNext ETF (159915) has surpassed 100 billion yuan in size, making it the largest ChiNext-related ETF in the market, with a management fee rate of only 0.15% per year [1] - In 2025, the tracking error of the E Fund ChiNext ETF (159915) is projected to be 0.45%, with an excess return of 2.24% compared to the ChiNext Index, ranking it first among comparable ETFs [1]

Core Viewpoint - The company focuses on the field of machine vision inspection equipment, with core products including 3D solder paste inspection (3D SPI) and 3D automated optical inspection (3D AOI) equipment, primarily used for quality control in the electronic assembly sector [1] Group 1: Product Applications - The company's products are mainly applied in quality inspection processes of PCB SMT production lines and semiconductor back-end packaging processes [1] - The products can also be utilized in the quality inspection stages of printed circuit board processes related to brain-computer interface devices [1]

脑机接口概念股跌幅居前，截至发稿，南京熊猫（600775）电子股份(00553)跌8.29%，报5.53港元；蓝 思科技（300433）(06613)跌5.74%，报28.26港元；脑动极光-B(06681)跌5.7%，报7.11港元；微创脑科学 (02172)跌2.23%，报13.15港元。 消息面上，南京熊猫此前发布股票交易异常波动公告称，公司主营业务聚焦智慧交通与平安城市、工业 互联网与智能制造、绿色服务型电子制造三大领域，目前未发生任何变化。截至目前，公司尚无与脑机 接口相关的成熟产品，亦未形成相关销售收入，相关概念不会对公司当前生产经营活动产生实质性影响 万联证券指出，短期内脑机接口商业化更多聚焦在非侵入式，中长期核心在（半）侵入/侵入式"柔性电 极+高通量低功耗芯片"等上游技术、多中心临床、合规标准等综合系统能力。行业政策支持和医保支 付、注册临床节点突破、核心技术突破和国产替代等均为未来行业发展催化剂。其中，侵入式关注研发 团队、临床资源、融资环境等；非侵入式关注品牌、渠道与成本控制等。 ...

Group 1 - The core viewpoint of the article highlights a significant decline in brain-computer interface concept stocks, with notable drops in companies such as Nanjing Panda Electronics, Lens Technology, BrainCo, and Micron Brain Science [1] - Nanjing Panda Electronics reported an 8.29% drop to HKD 5.53, while Lens Technology fell by 5.74% to HKD 28.26, BrainCo decreased by 5.7% to HKD 7.11, and Micron Brain Science dropped by 2.23% to HKD 13.15 [1] - Nanjing Panda has stated that its main business focuses on smart transportation, safe cities, industrial internet, and green service-oriented electronic manufacturing, with no current changes or mature products related to brain-computer interfaces [1] Group 2 - Wanlian Securities indicated that the commercialization of brain-computer interfaces is currently more focused on non-invasive methods, while the long-term core lies in (semi) invasive technologies, including flexible electrodes and high-throughput low-power chips [1] - Future industry development catalysts include policy support, medical insurance payments, breakthroughs in clinical registration nodes, core technology advancements, and domestic replacements [1] - For invasive methods, attention should be on research teams, clinical resources, and financing environments, while non-invasive methods should focus on branding, distribution channels, and cost control [1]

Group 1 - The A-share market experienced overall fluctuations on January 13, with the medical device ETF (562600) rising by 1.47%. AI medical applications continued to show strength, with stocks like Di'an Diagnostics hitting the daily limit, Tianzhihang-U increasing by 17.79%, and Hualan Biological rising by 10.64% [1] - The medical device ETF (562600) has seen significant capital inflow, with a net inflow of 140 million over the past five days and 162 million over the past ten days. As of 14:00, the trading volume of the ETF reached 56.14 million, indicating a notable increase in trading activity [1] - At the JPMorgan Healthcare Conference on January 12, Nvidia and Eli Lilly announced a joint investment of 1 billion over five years to establish a new research lab in the San Francisco Bay Area aimed at accelerating AI drug development [1] Group 2 - Analysts predict that the AI medical industry is entering a golden development period, with innovations in AI-assisted medical imaging, smart surgical robots, and AI platforms for drug development accelerating. The industry is expected to expand further as AI technology continues to develop and healthcare demands increase [2] - The medical device industry is thriving, and the medical device ETF (562600) provides a convenient way to capture growth opportunities. The ETF tracks the CSI All-Share Medical Device Index, with a 23.8% allocation to brain-computer interfaces, the highest among similar ETFs, and a significant focus on leading companies like Mindray and Di'an Diagnostics [2] - For external investors, options such as the Huaxia CSI All-Share Medical Device ETF Initiated Link A (021250) and Link C (021251) are available for convenient investment [2]

Group 1 - The AI+ healthcare sector experienced a significant surge on January 13, with the CSI Medical Equipment and Services Index rising by 1.62%, and several stocks, including Dean Diagnostics and Lanwei Medical, hitting the daily limit [1] - The Medical Equipment ETF (159873) recorded a trading volume exceeding 29 million yuan, with a turnover rate of 21.5%, both ranking first among similar products, and a real-time premium rate of 0.14% [1] - The ETF has seen a net inflow of funds for three consecutive trading days, totaling 7.5245 million yuan as of January 12, indicating strong investor interest [1] Group 2 - The Ministry of Industry and Information Technology is focusing on the large-scale application of humanoid robots and health monitoring devices in homes, communities, and elderly care institutions [2] - The Ministry of Civil Affairs introduced measures to cultivate elderly service operators and promote the silver economy, emphasizing the need for technological empowerment in elderly care services [2] - Guotai Junan Securities predicts continued growth in the medical equipment bidding scale, driven by ongoing equipment update policies, which are expected to boost procurement levels in the long term [2]

Core Insights - The medical device sector is expected to gradually recover in profitability, influenced by medical anti-corruption measures, high-value consumable procurement, and the implementation of equipment replacement policies [1] - The industry faced overall profit pressure in the first three quarters of 2025, but the gradual implementation of procurement reforms is anticipated to correct market distortions, leading to valuation recovery [1] - Emerging fields such as brain-computer interfaces, AI in healthcare, and surgical robots are gaining increased attention, which may catalyze growth in related sectors [1] Industry Trends - The surgical robot industry is entering a phase of commercialization and policy acceleration, with orthopedic surgical robot sales expected to grow by 17.81% year-on-year and sales revenue by 21.62% from January to November 2025, indicating a simultaneous increase in volume and price [1] - The National Healthcare Security Administration has established a pricing management framework for robotic surgeries, which is expected to enhance clinical penetration and drive the industry's development from quantitative to qualitative changes [1] - The laparoscopic robot sector is entering a phase of intensive approvals, with projections indicating that the installation volume in tertiary hospitals could exceed 4,000 units by 2030 [1] Investment Opportunities - The Medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies in the medical device, medical services, and medical information sectors from the A-share market to reflect the overall performance of Chinese medical-themed listed companies [1] - The CSI Medical Index comprises approximately 50 constituent stocks, concentrated in the pharmaceutical and healthcare sectors, characterized by high growth potential and volatility [1]

Group 1 - The A-share technology sector showed mixed performance in the afternoon, with AI applications and Sora concepts rising, while AI agents, brain-computer interfaces, and software development sectors experienced corrections [1] - OpenAI and SoftBank Group announced a joint investment of $1 billion to build an energy and data center supplier, focusing on enhancing data processing capabilities and energy efficiency for OpenAI's "Interstellar Gateway" infrastructure project [1] - The software industry plays a crucial role in the AI industry chain, providing core technical support and application implementation, with a focus on AI frameworks, development platforms, and algorithm models in the midstream technology layer [1] Group 2 - Guojin Securities reported that AI computing power demand is expected to remain strong through 2026, driven by increasing capital expenditures from North America's four major cloud providers and a significant rise in the number of AI server cabinets from Nvidia [2] - The report highlights a bullish outlook on the trends of increasing volume and price in AI-related products, including copper-clad laminates/PCBs, core computing hardware, and equipment [2]

当前市场情绪仍在，资金持续挖掘新机会，但商业航天操作难度较大，AI医疗则易集体加速。自2025 年底以来的这波热潮中，许多朋友可能因主线节奏极强而未能充分把握，从脑机接口到AI医疗，AI应 用领域集体加速、一致预期强烈，往往在爆发后才研究、瓦解时已来不及，容易后知后觉为他人做嫁 衣。因此，2026年想要做好投资，需大量持续跟踪，提前摸索储备逻辑，在关键节点敢于挑战人性，如 此方能避免关键时刻掉链子。 1月13日，和讯投顾余荣卓表示，2026年，你定会对市场有全新认知与收获。商业航天历经整整50天的 分歧转胜，自12月底起，紧绷的神经虽可稍作舒缓，但市场应用热度不减，工作赚钱的节奏依旧紧凑。 回顾近期市场，昨天本是不错的窗口期，然而AI医疗却意外走强。其直接导火索是英伟达与礼来计划 未来5年投入10亿美元共建联合实验室，但更本质的原因是医疗领域逻辑的持续累积与集体爆发。上周 火热的脑机接口、近期备受关注的ASS技术，均属AI医疗相关逻辑范畴；国内蚂蚁阿福、国外OpenAI 推出ChatGPT的Health功能，更是让这一领域热闹非凡，形成了AI医疗逻辑的持续叠加结构。 ...

Group 1 - The core viewpoint of the news highlights the strong performance of the innovative pharmaceutical sector, with the CSI Hong Kong Stock Connect Innovative Drug Index rising by 2.08% as of January 13, 2026, driven by significant gains in stocks such as Rongchang Bio (+9.38%), WuXi AppTec (+7.67%), and Tigermed (+7.66) [1] - Eight departments jointly issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'," emphasizing AI in drug development, AI-enabled pharmaceutical supply chains, surgical robots, and intelligent diagnostic systems as key development areas, with a goal to cultivate 2-3 ecosystem-leading enterprises by 2027 [1] - The integration of AI and healthcare is seen as a clear trend, with hardware companies represented by brain-computer interfaces and surgical robots expected to benefit from policy support and technological advancements [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Innovative Drug Index include WuXi Biologics, BeiGene, Innovent Biologics, and others, accounting for a total of 71.36% of the index [2] - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest closely tracks the CSI Hong Kong Stock Connect Innovative Drug Index, which includes stocks involved in innovative drug research and development, as well as services for pharmaceutical companies [2] - Investors without stock accounts can access the opportunities in the Hong Kong innovative drug industry through the Hong Kong Stock Connect Innovative Drug ETF linked fund [2]